Patents Issued in April 25, 2024
  • Publication number: 20240131111
    Abstract: A composition comprising BL-8040 (SEQ ID NO: 1) is disclosed herein, which may be for use in treating a condition treatable by BL-8040. The composition further comprises at least one compound characterized by a relative retention time of from 0.86 to 0.88 and/or a relative retention time of from 0.71 to 0.73 (wherein a relative retention time of BL-8040 is 1) under conditions described herein.
    Type: Application
    Filed: December 13, 2023
    Publication date: April 25, 2024
    Applicants: BioLineRx Ltd., Biokine Therapeutics Ltd.
    Inventors: Efrat HALBFINGER, Amnon PELED, Ella SORANI
  • Publication number: 20240131112
    Abstract: The present invention relates to a methanobactin reducing Fe3+ ions to Fe2+ ions for use in medicine and a pharmaceutical composition comprising said methanobactin as well as to a process for reducing Fe3+ ions to Fe2+ ions ex vivo.
    Type: Application
    Filed: February 1, 2022
    Publication date: April 25, 2024
    Inventors: Hans ZISCHKA, Alan Angelo DISPIRITO, Jeremy David SEMRAU
  • Publication number: 20240131113
    Abstract: Peptide-based therapies for a retinal disease, injury, or condition in a subject involve administering to the subject a pharmaceutical composition containing at least one peptide derived from a heat shock protein, including Hsp20 and ?B-crystallin. The administered peptides may be acetylated and/or conjugated to a cell-penetrating peptide. Administration of the peptides may reduce or prevent the loss of at least one retinal cell type, including retinal ganglion cells and retinal endothelial cells. The loss of such cells causes retinal damage and loss of eyesight in patients afflicted with an ocular condition. The pharmaceutical compositions may be administered intravitreally using an administration device. A single injection may be therapeutically sufficient for treating various ocular conditions.
    Type: Application
    Filed: February 22, 2022
    Publication date: April 25, 2024
    Inventors: Ram H. NAGARAJ, Rooban B. NAHOMI, Dorota L. STANKOWSKA
  • Publication number: 20240131114
    Abstract: The present disclosure relates to the field of biopharmaceuticals and provides a nerve growth factor (NGF) fusion protein and a preparation method and use thereof. The fusion protein has a general formula represented by A-B or A-L-B, wherein A is a nerve growth factor, L is a linker peptide, and B is an Fc moiety of IgG, or an analogue of the Fc moiety of IgG, or a fragment of the Fc moiety of IgG. The fusion protein of the present disclosure has the following advantages over a wild-type NGF: higher biological activity, a half-life extended more than 17 times, greatly reduced administration frequency, and significantly increased efficacy.
    Type: Application
    Filed: December 11, 2023
    Publication date: April 25, 2024
    Inventors: Qingshuang Zhang, Lei Ma, Ming Liu
  • Publication number: 20240131115
    Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.
    Type: Application
    Filed: December 22, 2023
    Publication date: April 25, 2024
    Inventors: Bai Liu, Peter Rhode, Wenxin Xu, Hing C. Wong
  • Publication number: 20240131116
    Abstract: Methods and therapeutic combinations are provided for treating idiopathic intracranial hypertension (IIH) and cluster headache, comprising administering a somatostatin mimetic such as octreotide formulated for direct nose-to-brain administration, and a carbonic anhydrase inhibitor such as topiramate or acetazolamide, at a dose level and/or dosing regimen lower than effective when administered alone.
    Type: Application
    Filed: February 23, 2022
    Publication date: April 25, 2024
    Applicant: NBO PHARMA LLC
    Inventors: Fredric D. PRICE, Barry R. FRANKEL, Dorian BEVEC, Warren WASIEWSKI
  • Publication number: 20240131117
    Abstract: The present invention relates to a collagenous marine invertebrate extract for use in the treatment of Epidermolysis Bullosa, pharmaceutical compositions comprising said collagenous marine invertebrate extract, and methods for manufacturing the collagenous marine invertebrate extract of the invention.
    Type: Application
    Filed: February 25, 2022
    Publication date: April 25, 2024
    Applicant: JELLAGEN LTD
    Inventors: Andrew Mearns SPRAGG, Almero BARNARD
  • Publication number: 20240131118
    Abstract: The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders.
    Type: Application
    Filed: April 5, 2023
    Publication date: April 25, 2024
    Inventors: Randall J. Mrsny, Tahir Mahmood
  • Publication number: 20240131119
    Abstract: The present application relates to the use of pertussis toxin, and its derivatives, analogs, salts and pharmaceutical equivalents. In one embodiment, the invention provides a method of treating or preventing a neurological disease or injury by administering pertussis toxin to the individual.
    Type: Application
    Filed: October 26, 2023
    Publication date: April 25, 2024
    Inventor: Jiong Shi
  • Publication number: 20240131120
    Abstract: Nanoparticles capable of delivering active pharmaceutical compounds (payload) into cells and methods of preparing same; wherein the payload is ionized and combined with a first polymer ion of an opposite charge resulting in the formation of an initial molecular assembly. The initial molecular assembly is then combined with a second polymer ion having an opposite charge and a different size than the first polymer ion, resulting in the formation of a secondary molecular assembly, wherein the payload becomes trapped between the first and the second polymer ions. The non-conjugated charged segments of the secondary molecular assembly are then repeatedly combined with additional polymer ions of alternating opposite charges to such segments charges and pre-determined size to extend and branch the molecular assembly resulting in the formation of a nanoparticle.
    Type: Application
    Filed: October 18, 2022
    Publication date: April 25, 2024
    Inventors: Oleg NEPOTCHATYKH, Evguenia NEPOTCHATYKH, Olga NEPOTCHATYKH
  • Publication number: 20240131121
    Abstract: The present invention provides a non-naturally occurring composition comprising a CRISPR nuclease comprising a sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 3 or a nucleic acid molecule comprising a sequence encoding the CRISPR nuclease.
    Type: Application
    Filed: April 5, 2023
    Publication date: April 25, 2024
    Applicant: EmendoBio Inc.
    Inventors: David Baram, Lior Izhar, Asael Herman, Liat Rockah, Nadav Marbach-Bar, Nurit Meron, Joseph Georgeson
  • Publication number: 20240131122
    Abstract: Described herein is a method of reducing virulence of a bacterial species with a segmented genome which has infected a mammalian host or mammalian host cell, by exposing the bacterial genome to an RNA-guided nuclease and a guide RNA (gRNA), thus generating a double-stranded or single-stranded break in the bacterial genome and causing loss of the targeted genome segment.
    Type: Application
    Filed: September 18, 2023
    Publication date: April 25, 2024
    Inventors: Yuko Nakajima, James E. Haber, Christine Jacobs-Wagner, Constantin N. Takacs
  • Publication number: 20240131123
    Abstract: The present disclosure provides food supplements comprising proteases that can digest a variety of food proteins to enhance their protein bioavailability in the gut.
    Type: Application
    Filed: August 21, 2022
    Publication date: April 25, 2024
    Inventors: Justin SIEGEL, Wai Shun MAK, John Bruce GERMAN
  • Publication number: 20240131124
    Abstract: Disclosed herein are structurally stabilized peptides of ACE2 helix 1 useful for diagnosing, preventing, and treating coronavirus infection by targeting the receptor binding domain of SARS-CoV-2 and thereby blocking its interaction with the human ACE2 receptor, which is involved in coronavirus infection and pathogenesis.
    Type: Application
    Filed: April 22, 2021
    Publication date: April 25, 2024
    Inventors: Loren D. Walensky, Henry D. Herce
  • Publication number: 20240131125
    Abstract: An enteric-coated oral dosage form comprising an acid labile active pharmaceutical ingredient where the composition is substantially free of monomeric phthalic acid esters and synthetic oils is described herein. Also provided are methods for making and using the enteric-coated oral dosage form. The disclosed pharmaceutical compositions comprise an enteric coating which includes at least one plasticizer, at least one film-forming agent and optionally at least one anti-sticking agent.
    Type: Application
    Filed: June 19, 2023
    Publication date: April 25, 2024
    Inventors: George Shlieout, Claus-Juergen Koelln, Frithjof Sczesny, Jens Onken, Andreas Koerner
  • Publication number: 20240131126
    Abstract: The invention relates to modified Factor IX coding sequence, expression cassette, vectors such as viral (e.g., lenti- or adeno-associated viral) vectors, and gene transfer methods and uses. In particular, to target Factor IX nucleic acid to cells, tissues or organs for expression (transcription) of Factor IX.
    Type: Application
    Filed: December 19, 2023
    Publication date: April 25, 2024
    Applicant: The Children's Hospital of Philadelphia
    Inventors: Katherine A. HIGH, Xavier ANGUELA
  • Publication number: 20240131127
    Abstract: The present invention relates to a modified neurotoxin single-chain polypeptide and a use thereof. The single-chain polypeptide contains a tagged protein, a linker short peptide, etc. The linker short peptide facilitates cleavage of the tagged protein, thereby improving purification of the single-chain polypeptide; in addition, the single-chain polypeptide has neurotoxicity when activated, but the single-chain polypeptide per se is only slightly toxic, such that the production safety is improved and the production process cost is reduced while the yield of the single-chain polypeptide is greatly increased.
    Type: Application
    Filed: February 24, 2022
    Publication date: April 25, 2024
    Inventor: Yan ZHANG
  • Publication number: 20240131128
    Abstract: Embodiments of the disclosure are related to a method of treating cancer including preventative treatment comprising administering nitrous oxide and oxygen and B-12 and/or folic acid to the patient, and/or administering a botulinum toxin to the patient by injection, wherein the latter is directed to preventative treatment.
    Type: Application
    Filed: December 21, 2023
    Publication date: April 25, 2024
    Inventor: Roland M. Williams
  • Publication number: 20240131129
    Abstract: Pharmaceutical composition for treating myasthenia gravis, comprising a carrier protein being SEQ ID NO:1 coupled to a plurality of a peptide epitope, the corresponding peptide epitopes and the method of synthesis of the conjugate.
    Type: Application
    Filed: February 28, 2022
    Publication date: April 25, 2024
    Applicant: CURAVAC EUROPE S.A.
    Inventors: Nicolas HAVELANGE, Stéphane HUBERTY
  • Publication number: 20240131130
    Abstract: The present invention is based, in part, on cancer vaccine compositions or pharmaceutical compositions comprising cancer cells, monocytes, and/or osteoclasts that activate NK cells, and methods for using same to prevent and/or treat diseases such as cancer.
    Type: Application
    Filed: February 17, 2022
    Publication date: April 25, 2024
    Inventor: Anahid Jewett
  • Publication number: 20240131131
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 18, 2023
    Publication date: April 25, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • Publication number: 20240131132
    Abstract: Antibodies that bind the tumor (T) antigen of the Merkel cell polyomavirus are disclosed. The antibodies can be use used in cell-based immunotherapies, antibody-based therapies, diagnostics, and detection assays, among other uses.
    Type: Application
    Filed: October 22, 2023
    Publication date: April 25, 2024
    Applicants: Fred Hutchinson Cancer Center, University of Washington
    Inventors: Justin J. Taylor, Denise Galloway, Paul Nghiem, David Koelle, Haroldo Rodriguez, Joseph Carter
  • Publication number: 20240131133
    Abstract: Described herein is a composition comprising nucleic acid sequences encoding at least two amino acid sequences selected from the group consisting of SEQ ID NOs: 1 to 247. Also described herein is a composition comprising nucleic acid sequences encoding at least two amino acid sequences selected from the group consisting of SEQ ID NOs: 6936 to 6994. Also described herein is a composition comprising nucleic acid sequences encoding at least two amino acid sequences selected from the group consisting of SEQ ID NOs: 12271 to 12396. Also described herein is a composition comprising nucleic acid sequences encoding at least two amino acid sequences selected from the group consisting of SEQ ID NOs: 49712 to 49814.
    Type: Application
    Filed: October 10, 2022
    Publication date: April 25, 2024
    Inventors: David Kenneth GIFFORD, Brandon CARTER
  • Publication number: 20240131134
    Abstract: An immunogenic composition, a periodontal vaccine formulation containing the immunogenic composition, and methods for treating or preventing periodontal disease are provided, where the methods involves administering an immunologically effective amount of the composition or vaccine formulation to a subject.
    Type: Application
    Filed: May 29, 2023
    Publication date: April 25, 2024
    Inventor: Jeffery FAIRMAN
  • Publication number: 20240131135
    Abstract: Disclosed herein are vaccine compositions for the treatment and prevention of urinary tract infections (UT!s) and methods for delivery of the vaccine compositions. Moreover, the disclosure provides adjuvant compositions for vaccines to modulate cellular responses. such as an immune response.
    Type: Application
    Filed: February 16, 2022
    Publication date: April 25, 2024
    Inventors: Soman Abraham, Jianxuan Wu
  • Publication number: 20240131136
    Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to sized Streptococcus pneumoniae serotype 6A capsular polysaccharides, in particular Streptococcus pneumoniae serotype 6A capsular polysaccharides having the average size (e.g. Mw) of the Streptococcus pneumoniae serotype 6A capsular polysaccharide is between 100-1000 kDa, suitably conjugated to a carrier protein.
    Type: Application
    Filed: November 1, 2023
    Publication date: April 25, 2024
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Elisabeth Marie Monique BERTAUD, Ralph Leon BIEMANS, Nicolas Jean Benoit MONIOTTE, Laurent Bernard Jean STRODIOT
  • Publication number: 20240131137
    Abstract: The present invention describes a second-generation tetanus toxoid vaccine and a process for the preparation thereof, comprising the steps of: inducing an E. Coli culture OD 600=0.5 by adding 0.2 mM IPTG; growing the culture at 14-16° C. for 14 to 20 hours; suspending the culture in 25 mM phosphate buffer containing 200 mM sodium chloride; adding 1% of triton-X-100 to the phosphate buffer, and adding the buffer to the culture; sonicating the culture for a period of 3 minutes (at 5 sec on/off pulse) at 4° C. on cold beads; centrifuging the culture for 60 to 90 minutes; collecting and purifying a supernatant using Ni-NTA affinity column with an eluant; and combining the supernatant into a pool with contaminated bands and concentrating using Centriprep-30 centrifuge filters (30 kDa pores).
    Type: Application
    Filed: September 13, 2023
    Publication date: April 25, 2024
    Applicant: Prime Bio, Inc.
    Inventor: Bal Ram Singh
  • Publication number: 20240131138
    Abstract: Chlamydiae are intracellular bacterial pathogens responsible for a variety of infections. The inventors produced an antibody that is directed against a surface antigen (i.e., CD40) of an antigen presenting cell (i.e., dendritic cell) wherein the heavy chain and/or light chain is conjugated to the MOMP VS4 domain of Chlamydia trachomatis for its use as vaccine.
    Type: Application
    Filed: December 22, 2021
    Publication date: April 25, 2024
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hopitaux de Paris (APHP), Baylor Research Institute, Universite Paris Est Creteil Val De Marne
    Inventors: Yves LEVY, Sylvain CARDINAUD, Mireille CENTLIVRE, Lydie DIEUDONNE, Sandra ZURAWSKI, Gérard ZURAWSKI
  • Publication number: 20240131139
    Abstract: Disclosed herein are subcutaneously administered, immunogenic compositions (e.g., vaccines) and methods of using and preparing the same. In some embodiments, the immunogenic compositions generate IgG antibodies to the spike proteins of the Wuhan-Hu-1, Delta B.1.617.2, and Omicron BA.1 variants of SARS-CoV-2 and may be suitable for use in preventing an infectious disease, such as SARS-CoV-2.
    Type: Application
    Filed: November 9, 2022
    Publication date: April 25, 2024
    Inventors: Michael Bowe, David Craig Wright
  • Publication number: 20240131140
    Abstract: Described are methods for the preparation of a HPV vaccine composition by, for example (i) adsorbing one or more HPV antigen(s) on a metallic salt and, then (ii) adding a non adsorbed glycolipid based TLR4 ligand to the mixture obtained in (i). Resulting HPV vaccine compositions and uses thereof are also described.
    Type: Application
    Filed: February 9, 2022
    Publication date: April 25, 2024
    Applicants: GLAXOSMITHKLINE BIOLOGICALS SA, XIAMEN INNOVAX BIOTECH CO., LTD.
    Inventors: Babak BAYAT, Véronique HENDERICKX, Bram VUYLSTEKE
  • Publication number: 20240131141
    Abstract: Disclosed herein are virus-like particle (VLP)-based bivalent vaccine compositions. The compositions may comprise a spherical retroviral Group-specific Antigen (“Gag”) protein core and at least two Ebola glycoproteins. The at least two Ebola glycoproteins may be located at the exterior surface of the spherical Gag protein core, such that the VLP-based vaccine presents at least two Ebola glycoprotein antigens. In one aspect, the at least two Ebola glycoproteins are a Zaire (EBOV) glycoprotein, and a Sudan (SUDV) glycoprotein.
    Type: Application
    Filed: December 21, 2023
    Publication date: April 25, 2024
    Inventors: Karnail Singh, Paul Spearman
  • Publication number: 20240131142
    Abstract: The present invention is directed to an artificial nucleic acid and to a polypeptide suitable for use in the treatment or prophylaxis of an infection with a flavivirus, in particular an infection with yellow fever virus or with dengue virus, or of a disorder related to such an infection. The present invention is also directed to a composition, preferably an immunogenic composition, comprising the artificial nucleic acid or the inventive polypeptide. In particular, the present invention concerns an immunogenic composition against a flavivirus, such as yellow fever virus or dengue virus. Further, the invention concerns a kit, particularly a kit of parts, comprising the artificial nucleic acid, polypeptide or (immunogenic) composition.
    Type: Application
    Filed: January 4, 2024
    Publication date: April 25, 2024
    Applicants: CureVac SE, Sanofi Pasteur
    Inventors: Patrick BAUMHOF, Wolfgang GROSSE, Edith JASNY, Thomas KRAMPS, Daniel VOSS, Julia DANNENMAIER, Valérie LECOUTURIER, Yves GIRERD-CHAMBAZ
  • Publication number: 20240131143
    Abstract: Described are methods of inducing a protective immune response against Lassa virus comprising administering a prophylactically effective amount of a nucleic acid molecule encoding a Lassa virus glycoprotein precursor (LASV GPC) to a subject in need thereof.
    Type: Application
    Filed: October 23, 2023
    Publication date: April 25, 2024
    Inventors: Kate Broderick, Kathleen A. Cashman, Jean D. Boyer, Scott M. White
  • Publication number: 20240131144
    Abstract: The present invention relates to formulations of dengue virus vaccine comprising at least one live, attenuated dengue virus or live, attenuated chimeric flavivirus, a buffer, a sugar, a cellulose derivative, a glycol or sugar alcohol, optionally an alkali or alkaline salt and an amino acid; and formulations of dengue virus vaccine comprising at least one live, attenuated dengue virus or live, attenuated chimeric flavivirus, a buffer, a sugar of at least 150 mg/ml, a carrier, and optionally an alkali or alkaline salt and an amino acid.
    Type: Application
    Filed: December 6, 2023
    Publication date: April 25, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Michael S. Ryan, Sherrie-Ann P. Martin, Morrisa Jones, Justin Stanbro, Akhilesh Bhambhani, Jeffrey Thomas Blue, Heidi Joanne Pixley, Erin J. Green-Trexler, Lynne Ann Isopi
  • Publication number: 20240131145
    Abstract: The instant disclosure relates to pseudovirus nanoparticles (PVNPs) and compositions comprising PVNPs. The disclosed PVNPs may be comprised of fusion proteins that form an icosahedral structure and a nanoparticle shell. The disclosed fusion proteins may comprise a modified norovirus (NoV) S domain protein; a hemagglutinin I (HA1) antigen of the influenza hemagglutinin I (HA1) of influenza vims; and a peptide linker connecting the C-terminus of the NoV S domain to the HA1 antigen. The modified NoV S domain proteins form the interior nanoparticle shell of said PVNP composition and display the 60 HA1 antigens on the surface of the nanoparticle shell. Methods of making and using the PVNPs and compositions containing PVNPs are also disclosed.
    Type: Application
    Filed: February 16, 2022
    Publication date: April 25, 2024
    Inventors: Ming TAN, Xi Jason JIANG
  • Publication number: 20240131146
    Abstract: A tetravalent dengue inactivated vaccine is provided, including a DENV-1 inactivated antigen, a DENV-2 inactivated antigen, a DENV-3 inactivated antigen, and a DENV-4 inactivated antigen. The tetravalent dengue inactivated vaccine with a good immune effect is prepared by using four serotypes of dengue viruses as virus seeds. Furthermore, the tetravalent dengue inactivated vaccine is capable of being preserved at 4° C. for a long time, possesses lasting and effective immunogenicity, produces higher antibody titer in mice and non-human primates, has good challenge protection capability on suckling mice, has no reproductive toxicity in the mice, and has good safety.
    Type: Application
    Filed: June 6, 2023
    Publication date: April 25, 2024
    Inventors: Jintao Li, Dong Hua, Minchi Liu, Hongxia Guo, Minyue Qiu
  • Publication number: 20240131147
    Abstract: The present invention provides polypeptides having a length of up to 180 amino acids and containing a sequence selected from sequences identical or differing at most in 5 amino acids from the sequence: KSELAVEILEKGQVRFWMQAX21X22X23X24GNAKVNYIFNEKEIFEGPKYKMHIDXsoXsiXszGIIEM FMEKLQDEDEGTYTFQLQX76X77X78X79X80NHSTVVLVGDVFKKLQKEAEFQRQEWIRKQG (SEQ ID NO. 2), wherein X21X22X23X24 is selected from KAQQ (SEQ ID NO. 33), LSVF (SEQ ID NO. 34), ATPS (SEQ ID NO. 35), EIMW (SEQ ID NO. 36), DGSS (SEQ ID NO. 37), LLPL (SEQ ID NO. 38), WMWW (SEQ ID NO. 39), MNLY (SEQ ID NO. 40), MWRN (SEQ ID NO. 41), IMME (SEQ ID NO. 42), KHQL (SEQ ID NO. 43), HWQF (SEQ ID NO. 44), YAGN (SEQ ID NO. 45) and HGQW (SEQ ID NO. 46); X50X51X52 is selected from RNT, IMF, GHE, PSW, RAN, YFW, ITL, QAM, DMR, WLW, QGE, VQY and VSL; X76X77X78X79X80 is selected from SHHLG (SEQ ID NO. 47), FMLMM (SEQ ID NO. 48), VILIL (SEQ ID NO. 49), IVTPL (SEQ ID NO. 50), DFIIW (SEQ ID NO. 51), MWSE (deletion) (SEQ ID NO. 52), LYYAW (SEQ ID NO. 53), MMIEY (SEQ ID NO.
    Type: Application
    Filed: February 18, 2022
    Publication date: April 25, 2024
    Inventors: Petr MALY, Milan RASKA, Milan KUCHAR, Petr KOSZTYU, Jiri CERNY, Veronika DANIEL LISKOVA, Hana PETROKOVA
  • Publication number: 20240131148
    Abstract: Provided herein are glycan engineered SARS-CoV-2 RBD polypeptides, fusion polypeptides comprising thereof, and immunogenic compositions comprising thereof. Also provided are methods of administering the RBD polypeptide, fusion polypeptide or immunogenic composition to a subject to elicit an immune response. Also provided are polynucleotides encoding the fusion polypeptide, and methods of administering a composition comprising the polynucleotide to a subject to elicit an immune response. In some embodiments, the polynucleotide is an RNA comprising modified ribonucleotides.
    Type: Application
    Filed: December 17, 2021
    Publication date: April 25, 2024
    Inventors: William R. SCHIEF, Torben SCHIFFNER, Jon M. STEICHEN, Xiaozhen HU
  • Publication number: 20240131149
    Abstract: The present invention relates to an isolated polypeptide that finds utility in generating an immune response against a virus in a subject. Also disclosed are immunogenic compositions comprising the isolated polypeptide, generating an immune response against a virus in a subject, and preventing or treating a viral infection in a subject, in particular a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
    Type: Application
    Filed: February 24, 2022
    Publication date: April 25, 2024
    Inventor: PRIYANK SHUKLA
  • Publication number: 20240131150
    Abstract: Provided herein are therapeutic nucleic acid molecules for managing, preventing and/or treating infectious diseases caused by coronavirus. Also provided herein are therapeutic compositions, including vaccines and lipid nanoparticles, comprising the therapeutic nucleic acids and related therapeutic methods and uses.
    Type: Application
    Filed: December 1, 2023
    Publication date: April 25, 2024
    Inventor: Bo Ying
  • Publication number: 20240131151
    Abstract: The present application relates to an immunostimulatory composition including a liposome-nucleic acid complex wherein said complex contains (1) a liposome which, interms of its lipids, includes or consists of a first lipid and a second lipid, wherein the first lipid is a zwitterionic lipid and the second lipid is a cationic lipid, and (2) one or more immunostimulatory oligonucleotides and/or one or more polynucleotides. The application further relates to certain uses of the immunostimulatory composition and to methods for preparing the same. In particular, the application concerns the use of a zwitterionic lipid in an immunostimulatory composition including a liposome-nucleic acid complex to induce type I interferon immune responses and/or to reduce or even bypass TLR-mediated immune responses.
    Type: Application
    Filed: October 19, 2022
    Publication date: April 25, 2024
    Inventors: Simone Marlene Putzke, Thomas Ilg, Elisabeth Feldhues, Iris Heep, Alf Lamprecht
  • Publication number: 20240131152
    Abstract: This invention describes ways of obtaining nano-particulated adjuvants formed by different synthetic variants of GM3 ganglioside. Depending on the fine structure of the fatty acid in the ceramide of the synthetic GM3, said adjuvants are able to stimulate specifically and in a specialized way the humoral or cellular immune response against accompanying antigens. Particularly, this invention provides immunogenic vaccine compositions that comprise peptides, polypeptides or proteins and the aforementioned nanoparticles, which are formed through the dispersion of hydrophobic proteins of the outer membrane complex (OMC) of Neisseria meningitidis in solutions containing fully synthetic variants of the GM3 ganglioside.
    Type: Application
    Filed: October 2, 2023
    Publication date: April 25, 2024
    Inventors: Luis Enrique Fernández Molina, Belinda Sánchez Ramírez, Audry Fernández Gómez, Gretchen Bergado Báez, Circe Mesa Pardillo, Lisset Chao García, Narjara González Suárez, Dayana Pérez Martínez, Diana Rosa Hernández Fernández, Mabel Cruz Rodríguez, Ángel Alexis Manso Vargas, Vicente Guillermo Verez Bencomo, Blanca Idelmis Tolón Murguía, Miguel Antonio López López, Jesús Arturo Junco Barranco
  • Publication number: 20240131153
    Abstract: Compositions and methods for treating rheumatoid arthritis and/or accelerated atherosclerosis are provided, including an inhibitor of oxidized or malondialdehyde-modified low density lipoprotein (LDL) for administration to a subject. Exemplary inhibitors of oxidized LDL include an anti-oxidized LDL antibody, which results in a reduction in the secretion of pro-inflammatory cytokine from primary monocyte in vitro and the plasma cytokine level of inflammatory cytokine in vivo.
    Type: Application
    Filed: May 21, 2023
    Publication date: April 25, 2024
    Inventors: Bertrand C. LIANG, Stacey RUIZ, Christopher John FARINA
  • Publication number: 20240131154
    Abstract: Disclosed herein is a composition comprising a recombinant nucleic acid sequence that encodes an antibody to a Zika viral antigen, and functional fragments thereof. The invention also relates to a composition comprising the combination of a first composition that elicits an immune response in a mammal against zika virus and a second composition comprising a recombinant nucleic acid sequence encoding an antibody, a fragment thereof, a variant thereof, or a combination thereof. In some instances, the nucleic acid molecule comprises a nucleotide sequence encoding an anti-ZIKV-Envelope (anti-ZIKV E) Protein antibody.
    Type: Application
    Filed: September 28, 2023
    Publication date: April 25, 2024
    Inventors: David Weiner, Karuppiah Muthumani, Jian Yan
  • Publication number: 20240131155
    Abstract: The invention provides inter alia an engineered T cell, wherein said T cell is engineered to express a T cell receptor (TCR) or an antibody-based receptor that binds to a T cell epitope of human ropporin-1A (ROPN1) or human ropporin-1B (ROPN1B); wherein said T cell epitope is selected from the group consisting of SEQ ID NO:4, SEQ ID NO:43, SEQ ID NO:23, SEQ ID NO:56 and SEQ ID NO:24.
    Type: Application
    Filed: January 21, 2022
    Publication date: April 25, 2024
    Inventors: Johannes Eduard Maria Antonius DEBETS, Dora Martha HAMMERL
  • Publication number: 20240131156
    Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from the differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
    Type: Application
    Filed: October 18, 2020
    Publication date: April 25, 2024
    Inventors: Bahram VALAMEHR, Ryan BJORDAHL, Tom Tong LEE, Jode GOODRIDGE
  • Publication number: 20240131157
    Abstract: Disclosed herein are chimeric antigen receptor (CAR) polypeptides that can be used with adoptive cell transfer having endodomains with a customized number of immunoreceptor tyrosine-based activation motifs (ITAMs). In some embodiments, the endodomain has a backbone of a receptor endodomain, such as CD8, CD3?, CD3?, CD3?, CD3?, CD32 (Fc gamma RIIa), DAP10, DAP12, CD79a, CD79b, Fc?RI?, Fc?RIII?, Fc?RI? (FCERIB), and Fc?RI? (FCERIG). In particular embodiments disclosed herein, the backbone is a DAP12 backbone. The disclosed endodomain is engineered to express at least one heterologous ITAM, including 1, 2, 3, 4, 5, or 6 ITAMs.
    Type: Application
    Filed: February 15, 2022
    Publication date: April 25, 2024
    Inventor: Marco L. Davila
  • Publication number: 20240131158
    Abstract: Methods of using polypeptides to modulate transforming growth factor-? (TGF?) signaling (e.g., TGF? receptors, antibodies or antigen-binding fragments thereof that specifically bind TGF? or a TGF? receptor) are provided. Compositions comprising the antibodies or fragments thereof and methods of using the same for treatment of diseases involving TGF? activity are provided. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions comprising these antigen binding agents and fragments thereof are also disclosed. The invention also provides therapeutic methods for utilizing the TGF? signaling modulators are provided herein.
    Type: Application
    Filed: February 15, 2022
    Publication date: April 25, 2024
    Inventors: Chantal KUHN, Gary SHAPIRO
  • Publication number: 20240131159
    Abstract: Provided herein are mutants of estrogen receptor alpha ligand binding domain (ER-LBD), and chimeric proteins including such mutant ER-LBD. Also provided are methods of modulating transcription and modulating localization of such chimeric proteins.
    Type: Application
    Filed: October 4, 2023
    Publication date: April 25, 2024
    Inventors: Michelle Elizabeth Hung, Rebecca Tayler Cottman, Russell Morrison Gordley, Gary Lee, Timothy Kuan-Ta Lu, Srinivasaraghavan Kannan, Chandra Shekhar Verma
  • Publication number: 20240131160
    Abstract: The present invention includes compositions and methods for an DPP6 specific chimeric antigen receptor (CAR). In certain embodiments the DPP6 specific CAR is expressed on a T regulatory cell. In certain embodiments, the DPP6 specific CAR is used to treat type 1 diabetes.
    Type: Application
    Filed: March 1, 2022
    Publication date: April 25, 2024
    Inventors: James L. Riley, Gavin Ellis